Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hikma Pharmaceuticals PLC (HIK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,982.50-35.50 (-1.76%)
At close: 04:35PM GMT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2,018.00
Open2,011.00
Bid1,981.50 x 0
Ask1,983.00 x 0
Day's Range1,976.00 - 2,043.00
52 Week Range1,976.00 - 2,703.00
Volume303,199
Avg. Volume424,293
Market Cap4.589B
Beta (5Y Monthly)-0.11
PE Ratio (TTM)13.37
EPS (TTM)148.30
Earnings DateFeb 24, 2022
Forward Dividend & Yield0.38 (1.87%)
Ex-Dividend DateAug 19, 2021
1y Target Est27.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HIK.L

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Hikma Ventures leads Series A extension in NuvoAir to support its platform for patient-centric care and clinical trials

      Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has led a $11 million USD round of financing for NuvoAir, a leading digital health company for chronic disease management and decentralized clinical trials that focuses on complex patients, initially targeting respiratory conditions such as COPD and asthma. The investment is an extension of the Series A round that was previously announced by NuvoAir in June 2021. Th

    • PR Newswire

      Hikma expands into Canada with acquisition of Teligent sterile injectable assets

      Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.

    • PR Newswire

      Hikma Launches New 503B Sterile Compounding Business

      Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, announces the launch of Hikma 503B – a new outsourced sterile compounding business focused on providing high quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the United States.

    Advertisement
    Advertisement